Insilico Medicine

Focus: Insilico Medicine is an AI-driven in silico drug discovery company headquartered in Hong Kong, specializing in computational approaches to identify and develop novel therapeutics across aging research and oncology indications.

Aging Research

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Insilico Medicine

AI assessmentNot Hiring

No open roles listed right now. Follow Insilico Medicine to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

9 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

ISM8207

Advanced Solid Tumors

Phase 1

Clinical Trials (1)

NCT06445517Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma

Phase 1

Help build intelligence for Insilico Medicine

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Cutting-edge AI/computational platform for drug discovery—opportunity to work at the intersection of pharma and machine learning rather than traditional medicinal chemistry
Diverse pipeline spanning oncology (3 Phase 1 solid tumor programs), fibrosis (Phase 2 IPF candidate), and GI (Phase 2 UC program) offers exposure to multiple therapeutic areas
Early-stage company with 9 active clinical programs suggests rapid advancement opportunity and direct impact on company trajectory

Watch Out For

Only 1 active job opening signals extremely limited hiring despite 9 programs in development—difficult entry point for most career stages
No marketed products, Phase 3 programs, or disclosed financials indicate pre-revenue stage with uncertain runway and funding sustainability

Generated by Claude from Insilico Medicine's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

INS018_055

Idiopathic Pulmonary Fibrosis

Phase 1

Clinical Trials (1)

NCT05154240A Phase 1, Evaluate the Safety, Tolerability, and Pharmacokinetics of INS018_055 in Healthy Subjects

Phase 1

ISM5411

Healthy Subjects

Phase 1

Clinical Trials (1)

NCT06012578Study Evaluating ISM5411 Administered Orally to Healthy Volunteers

Phase 1